What Causes Blood In Urine: 9 Common And Serious Conditions 

Noticing blood in your urine—whether as a subtle change picked up on a routine test or as a striking, visible red or brownish tinge—can be deeply unsettling. Known medically as haematuria, this symptom ranges from the microscopic (only seen under a microscope) to the grossly visible, each with its own implications. Sometimes, the cause is benign and easily treated; at other times, it can signal something far more serious requiring urgent attention.

Because haematuria is such a broad sign, pinpointing the underlying reason is crucial. The potential causes span from everyday infections and minor irritations to kidney disease, tumours, or inherited conditions. Knowing when to seek help and understanding what might be behind this symptom can make all the difference in outcomes and peace of mind.

This article breaks down nine of the most common and serious causes of blood in urine. You’ll find clear explanations for each, practical clues to help you recognise key symptoms and red flags, and straightforward advice on what steps to take next. Whether you’re seeking reassurance or considering a private consultation for discreet, specialist care, you’re in the right place to get informed and take control of your health journey.

1. Urinary Tract Infections (UTIs)

A urinary tract infection (UTI) occurs when bacteria—most commonly Escherichia coli—ascend the urethra and colonise the bladder lining. The resulting inflammation disrupts the normal barrier function of the urothelium, allowing red blood cells to leak into the urine. In women, UTIs are particularly common; up to 50 percent will experience at least one episode in their lifetime. Although a simple lower UTI is rarely life-threatening, it can cause both gross and microscopic haematuria and warrants prompt diagnosis and treatment.

Diagnosing a UTI typically involves a mid-stream urine sample for dipstick testing (to detect nitrites, leukocyte esterase and blood) followed by microscopy and culture to identify the organism and its antibiotic sensitivities. While most uncomplicated UTIs resolve with first-line antibiotics—such as nitrofurantoin or trimethoprim according to UK guidelines—adequate fluid intake and symptomatic relief with analgesics (e.g., paracetamol or ibuprofen) are also crucial.

Certain presentations demand referral to a urologist or hospital setting. Men presenting with a first UTI, any patient with recurrent infections (more than two episodes in six months), or signs suggestive of upper tract involvement should be investigated further. For advice on persistent or recurring bladder infections, see our page on recurrent UTIs.

1.1 Symptoms and Red Flags

Typical symptoms of a lower UTI include:

• Dysuria (burning sensation on passing urine)
• Urinary frequency and urgency
• Suprapubic discomfort or tenderness
• Cloudy or malodorous urine
• Occasional gross haematuria (visible blood) or microscopic haematuria

Red flags that require urgent review include:

• Fever or rigors—suggesting pyelonephritis
• Flank or loin pain, nausea and vomiting
• Signs of systemic sepsis (tachycardia, hypotension)
• Inability to tolerate oral fluids or medications

1.2 Management and Prevention

Self-care and lifestyle adjustments can lower the risk of recurrent bladder infections:

• Drink at least 1.5–2 litres of water daily to flush the urinary tract
• Empty your bladder before and after sexual intercourse
• Wipe from front to back to reduce bacterial spread
• Avoid potentially irritating feminine hygiene products

Evidence for cranberry products is mixed; they may help some women but are not a substitute for antibiotics. If you experience more than two UTIs in six months or have persistent symptoms despite treatment, discuss preventive strategies—such as low-dose prophylaxis or post-coital single-dose antibiotics—with your urologist.

2. Kidney Infections (Pyelonephritis)

A kidney infection, or pyelonephritis, occurs when bacteria ascend from the bladder into one or both kidneys or, less commonly, arrive via the bloodstream. As the renal tissue becomes inflamed, its tiny vessels can leak red blood cells into the urine, producing gross or microscopic haematuria. Unlike a simple lower urinary tract infection, pyelonephritis often makes you feel distinctly unwell and carries a higher risk of complications if not treated swiftly.

Certain groups—particularly people with diabetes, those who are immunocompromised, or anyone with urinary tract abnormalities—are more susceptible to severe infections. Prompt diagnosis and appropriate therapy are essential to prevent renal scarring, abscess formation or even life-threatening sepsis. Standard evaluation includes both urine and blood cultures, plus imaging if an abscess or obstruction is suspected.

For further details on definition and best-practice guidelines, refer to the NIDDK’s overview of kidney infection (pyelonephritis).

2.1 Clinical Presentation

Patients with pyelonephritis typically report:

• High fever (often above 38.5 °C) accompanied by chills or rigors
• Flank or loin pain, usually one-sided but sometimes bilateral
• Nausea, vomiting and general malaise
• Dysuria, urgency or frequency if concurrent cystitis is present
• Gross haematuria or microscopic blood on dipstick

On examination, tenderness over the costovertebral angle (CVA) is common, and vital signs may show tachycardia or hypotension if the infection is systemic. In elderly or immunosuppressed patients, the presentation can be more subtle—look for altered mental status, decreased urine output or unexplained chest signs.

2.2 Treatment Considerations

Management hinges on infection severity and patient factors:

Outpatient Therapy

• For stable adults with no significant comorbidity: oral antibiotics such as a fluoroquinolone (e.g. ciprofloxacin) or trimethoprim–sulfamethoxazole, tailored to culture sensitivities.
• Duration usually spans 7–14 days, depending on clinical response and local guidance.
• Encourage adequate hydration and analgesia (paracetamol or NSAIDs) to ease discomfort.

Inpatient Admission

• Indications include high fever with rigors, intractable vomiting, signs of sepsis (e.g. hypotension, tachycardia), inability to tolerate oral intake or significant comorbidities (diabetes, immunosuppression, pregnancy).
• Initiate intravenous broad-spectrum antibiotics—commonly a third-generation cephalosporin or an aminoglycoside combination—then de-escalate based on culture results.
• Monitor renal function, fluid balance and inflammatory markers; arrange imaging (ultrasound or CT) if you suspect an abscess or obstruction.

Follow-up

• Reassess urine cultures 48–72 hours post-treatment start to confirm bacteriological clearance.
• In recurrent cases or where structural abnormality is suspected, consider referral for renal tract imaging and specialist urology input.

3. Bladder or Kidney Stones

Bladder or kidney stones form when minerals crystallise and aggregate within the urinary tract. Most stones are made of calcium oxalate, but other types include uric acid and struvite stones. As these hard deposits move or grow, they can scrape against the lining of the ureter, bladder or renal pelvis, causing mucosal irritation and leading to visible or microscopic haematuria.

Typical symptoms include sudden, severe flank or loin pain—often referred to as renal colic—that may radiate towards the groin. Nausea and vomiting frequently accompany the pain, and patients may notice blood in the urine when viewed in the toilet or detected on dipstick testing. The intensity of discomfort usually prompts urgent medical review.

Diagnosing urinary stones begins with imaging. An ultrasound is a radiation-free method ideal for initial assessment, especially in children and pregnant patients. However, the gold standard is a non-contrast CT scan of the kidneys, ureters and bladder (CT KUB), which accurately identifies stone size, density and location.

Acute management focuses on pain relief, hydration and facilitation of stone passage. Strong analgesia—typically non-steroidal anti-inflammatory drugs (NSAIDs) or opioid sparing options—is given alongside intravenous or oral fluids to encourage stone expulsion. In selected cases, medical expulsive therapy with an alpha-blocker (for example, tamsulosin) can increase the likelihood of spontaneous passage for stones under 6 mm. If stones are too large or complications such as obstruction arise, urological interventions like extracorporeal shock wave lithotripsy (ESWL) or ureteroscopy may be necessary.

Long-term prevention is equally important to reduce recurrence. Dietary and lifestyle modifications tailored to the stone type can cut the risk of new stones forming. For detailed nutritional advice, see the kidney stone diet plan and prevention guidelines.

3.1 Types and Risk Factors

Patients with metabolic syndromes, a family history of stones or certain chronic conditions (such as inflammatory bowel disease) face higher stone recurrence rates. A thorough metabolic work-up may include serum calcium, uric acid and parathyroid hormone levels.

3.2 Prevention Strategies

Effective prevention begins with adequate hydration—aim for 2–3 litres of fluid daily to dilute urinary solutes. Beyond water, limiting individual dietary components can help:

• Calcium: Maintain normal dietary calcium; avoid excessive calcium supplementation.
• Sodium: Restrict sodium intake to under 2 g per day to reduce urinary calcium excretion.
• Animal Protein: Moderate consumption of red meat and shellfish to lower acid load and uric acid production.
• Oxalate: Limit high-oxalate foods (rhubarb, spinach, nuts) and pair them with calcium-rich meals to bind oxalate in the gut.
• Vitamin C: Avoid megadoses—high doses can increase oxalate formation.

A tailored prevention plan may also include thiazide diuretics for hypercalciuria or allopurinol for recurrent uric acid stones. Regular follow-up with imaging and metabolic testing ensures early detection of new stone formation. For a comprehensive dietary framework, explore the kidney stone diet plan and prevention resource.

4. Benign Prostatic Hyperplasia (BPH)

Benign prostatic hyperplasia, or BPH, describes the non-cancerous enlargement of the prostate gland that typically occurs as men age. The prostate sits just below the bladder and surrounds the urethra; as it enlarges, it compresses the urethral lumen and increases bladder outlet resistance. This elevated pressure can make small blood vessels within the bladder neck and prostatic urethra more prone to rupture, resulting in episodes of visible or microscopic haematuria.

Men with BPH often report progressive lower urinary tract symptoms (LUTS), such as hesitancy when starting to pass urine, a weak or intermittent stream, nocturia (needing to get up at night), and the sensation of incomplete bladder emptying. Although these symptoms are usually the first to prompt medical review, intermittent haematuria—particularly after straining—may be the presenting complaint in up to 20 percent of patients. Early investigation helps to distinguish BPH-related bleeding from other urological causes, including malignancy or stone disease.

Common investigations include:

• Measurement of prostate-specific antigen (PSA) to assess prostate volume and to exclude prostate cancer in appropriate clinical context.
• Uroflowmetry or flow rate studies, which quantify peak urinary flow and post-void residual volume.
• Transabdominal or transrectal ultrasound to evaluate prostate size, bladder wall thickness and any diverticula or stones.

4.1 Recognising BPH-Related Bleeding

Bleeding due to BPH usually manifests as intermittent, low-volume haematuria often linked to episodes of increased intravesical pressure—such as straining or prolonged voiding. Unlike the persistent, heavy bleeding seen with bladder tumours or stone erosion, BPH-related haematuria tends to settle spontaneously and is not typically associated with severe colicky pain.

Red flags that should prompt further evaluation include:

• Persistent or worsening haematuria despite conservative measures
• Clots leading to urinary retention
• New-onset irritative symptoms (urgency, frequency) without clear infection
• Unexplained weight loss or bone pain (potential markers for malignancy)

Any atypical pattern or concern on initial imaging and flow studies warrants referral for cystoscopy and urological assessment.

4.2 Treatment Approaches

Management of BPH focuses on symptom relief, reduction of prostate volume and prevention of complications such as recurrent bleeding. Options include:

1. Watchful waiting

   • For men with mild symptoms and infrequent bleeding, lifestyle modifications (reducing evening fluid intake, bladder training) and regular monitoring may suffice.

2. Medical therapy

   • Alpha-blockers (e.g., tamsulosin, alfuzosin) relax smooth muscle in the prostate and bladder neck, improving flow and lowering intravesical pressure.
   • 5-alpha-reductase inhibitors (finasteride, dutasteride) shrink prostate volume over several months and reduce vascularity, which can decrease the risk of bleeding.

3. Minimally invasive or surgical interventions

   • In patients who fail medical therapy or who develop complications (significant haematuria, urinary retention), procedures such as transurethral resection of the prostate (TURP), laser enucleation or newer techniques (prostatic artery embolisation, UroLift®) can provide durable relief, reduce bleeding and improve quality of life.

Decisions should be tailored to each patient’s symptom severity, comorbidities and preference, with discussion around potential side effects—such as sexual dysfunction—with alpha-blockers and 5-alpha-reductase inhibitors.

5. Glomerulonephritis and Other Kidney Diseases

Glomerulonephritis covers a spectrum of disorders characterised by inflammation of the kidney’s filtering units (the glomeruli). When these tiny capillary tufts become inflamed, their normally tight barrier loosens, allowing red blood cells—and often protein—to escape into the urine. The result is usually microscopic haematuria, sometimes accompanied by visible, cola-coloured urine, swelling (oedema), high blood pressure and fatigue.

These diseases may arise primarily in the kidneys or develop secondary to systemic conditions. IgA nephropathy, post-streptococcal glomerulonephritis and lupus nephritis are among the most frequently encountered. Hereditary syndromes such as Alport syndrome—where a collagen IV defect weakens the glomerular basement membrane—also lead to persistent haematuria and progressive renal decline. Identifying the precise type of glomerular injury early can prevent irreversible damage and slow progression towards chronic kidney disease.

5.1 Types of Glomerular Disease

5.2 Investigations and Management

Work-up begins with blood tests—serum creatinine and estimated glomerular filtration rate (eGFR)—to assess renal function. Urinalysis detects the degree of haematuria and quantifies proteinuria. Serological markers such as antinuclear antibodies (ANA), complement levels and anti-streptococcal titres help pinpoint an underlying systemic or post-infectious cause. If non-invasive investigations are inconclusive, or if treatment hinges on precise histological diagnosis, a renal biopsy is indicated.

Management is tailored to the specific glomerular disorder:

• Immunosuppressive regimens (corticosteroids, cyclophosphamide or mycophenolate mofetil) are central to treating aggressive forms of GN, such as rapidly progressive or severe lupus nephritis.
• Blood pressure control—preferably using ACE inhibitors or angiotensin receptor blockers—reduces glomerular hypertension, curbs proteinuria and slows disease progression.
• Supportive measures include dietary salt restriction, diuretics for oedema and lipid-lowering agents when needed.

Hereditary nephropathies warrant early intervention: ACE inhibitors may be introduced even in mild stages to preserve renal function. Throughout treatment, regular monitoring of renal parameters, blood pressure and urinary findings is vital. Collaboration with a nephrologist ensures prompt adjustment of therapy and minimises the risk of long-term complications.

6. Bladder or Kidney Cancer

In the UK, around 10,300 new cases of bladder cancer are diagnosed each year, while renal cell carcinoma (kidney cancer) represents roughly 3 per 100,000 people annually. Both malignancies often herald themselves with painless haematuria—visible red or brown urine, or blood detected only on laboratory testing. Prompt investigation of any unexplained bleeding can be life-saving.

Bladder cancer arises from the urothelial lining, whereas renal cell carcinoma originates in the kidney’s tubular cells. Early stages may be asymptomatic apart from intermittent bleeding, but additional warning signs can include:

• Unintentional weight loss or loss of appetite
• Dull flank or loin discomfort
• Persistent lower urinary tract symptoms (frequency, urgency, dysuria) without evidence of infection

Diagnostic work-up centres on direct visualisation and imaging. Flexible cystoscopy allows a urologist to inspect the bladder lining and obtain biopsy samples. A CT urogram then provides high-resolution images of the entire urinary tract, while ultrasound offers a swift, radiation-free scan of the kidneys and bladder.

Treatment depends on tumour type, stage and patient fitness, and often combines local and systemic approaches:

• Transurethral resection of bladder tumour (TURBT) followed by intravesical therapy for non-muscle invasive disease
• Partial or radical nephrectomy—removal of all or part of the kidney—for localised renal tumours
• Targeted therapies or immunotherapy for advanced or metastatic disease

Early detection and tailored treatment significantly improve survival rates. Any episode of unexplained haematuria should trigger immediate assessment to confirm or exclude malignancy and start appropriate management.

6.1 Risk Factors and Warning Signs

Key risk factors for bladder and kidney cancers include:

• Smoking: the leading cause of urothelial malignancy
• Occupational exposures: aromatic amines in dye-, rubber- or textile-manufacturing
• Chronic bladder irritation: long-term catheterisation or recurrent infections
• Hereditary syndromes: for example, von Hippel–Lindau disease

Warning signs that raise suspicion of cancer rather than benign causes include persistent, non-cyclical bleeding, unexplained night sweats, palpable abdominal masses or a significant history of pelvic radiation. A detailed occupational and family history is essential.

6.2 Diagnostic Pathway

Primary care assessment for visible haematuria in patients aged 45 and over should follow NICE NG12 recommendations for suspected cancer. Initial investigations often comprise:

• Full blood count and renal function
• Urine cytology to detect malignant urothelial cells
• Ultrasound as a rapid screen for upper tract lesions

Definitive diagnosis and staging then rely on cystoscopy to visualise and sample bladder lesions, and a CT urogram to map both upper and lower urinary tracts. Close collaboration between urology, radiology and oncology teams ensures patients move swiftly from suspicion to specialist care in a discreet, supportive environment.

7. Inherited Blood Disorders (Sickle Cell, Alport Syndrome)

Inherited blood disorders may first manifest in the kidneys, most commonly through episodes of blood in the urine. In sickle cell disease, the classic sickling of red blood cells can block the tiny vessels of the renal medulla, leading to papillary necrosis and intermittent haematuria. Alport syndrome arises from a genetic defect in type IV collagen within the glomerular basement membrane, causing persistent microscopic or gross haematuria accompanied by hearing and vision changes. Spotting these hereditary clues early can be a real game-changer, as targeted therapies and careful monitoring help slow kidney damage.

7.1 Sickle Cell-Related Haematuria

In sickle cell anaemia, deoxygenated red blood cells become rigid and crescent-shaped. As they pass through the low-oxygen environment of the renal medulla, they tend to clump together and obstruct microvasculature. One result is papillary necrosis—damage to the tips of the renal pyramids—which then bleeds into the collecting system. Patients often report episodic dark or red urine, especially after exertion or dehydration, though sometimes blood is detected only on microscopy.

Diagnosis relies on haemoglobin electrophoresis or genetic analysis to confirm the sickle mutation. Clinically, look out for a family history of sickle cell trait or disease and episodes of pain crises. Management focuses on good hydration, pain control, and in children, prophylactic penicillin. Hydroxyurea or newer agents that boost fetal haemoglobin can reduce sickling events. Regular follow-up with urinalysis and renal function tests helps catch any chronic changes before they escalate.

7.2 Hereditary Nephropathies

Alport syndrome and related nephropathies remind us that kidney disease can be part of a broader inherited disorder. Mutations in the COL4A3, COL4A4 or COL4A5 genes weaken the glomerular basement membrane, leading to lifelong microscopic haematuria and, often, progressive proteinuria. The presence of sensorineural hearing loss—typically emerging in adolescence—and eye findings like anterior lenticonus often clinch the diagnosis.

Confirming Alport syndrome requires genetic testing, supported by audiology and ophthalmology assessments to map the full extent of collagen defects. Early use of ACE inhibitors or angiotensin receptor blockers slows proteinuria and preserves glomerular filtration rate. Beyond blood pressure control, patients benefit from dietary advice (salt moderation), anaemia management and close collaboration with ENT and eye specialists. Ongoing partnership with a nephrologist ensures that any decline in kidney function is identified and managed promptly, giving patients the best chance of a stable outcome.

8. Medications That Can Cause Haematuria

While we often focus on infections, stones or prostate issues when investigating haematuria, it’s important not to overlook medications as potential offenders. Several drug classes can disrupt normal clotting or irritate the urinary tract lining, leading to visible or microscopic blood in the urine. A thorough drug history—encompassing prescribed, over-the-counter and herbal remedies—is essential to identify and manage these cases.

Patients and clinicians alike should remain vigilant: adjusting doses, switching agents or introducing protective measures can often resolve drug-related bleeding without sacrificing therapeutic benefit.

8.1 Common Culprit Drugs

When a patient on any of these medications presents with haematuria, pause to consider whether the timing and severity of bleeding align with pharmacological effects. Some newer agents, like direct oral anticoagulants (DOACs), carry a lower monitoring burden than warfarin but still pose a significant bleeding risk—particularly in the elderly or those with impaired renal function.

8.2 Monitoring and Mitigation

Effective management hinges on balancing the risk of bleeding against the therapeutic need for the drug. Strategies include:

• Warfarin monitoring: maintain INR within target range (usually 2.0–3.0 for most indications). If haematuria develops with an INR above range, consider temporary dose reduction or reversal with vitamin K.
• DOAC dose review: ensure dosage matches age, weight and renal function. Hold therapy briefly if bleeding is substantial and liaise with haematology regarding specific reversal agents (e.g., andexanet alfa for factor Xa inhibitors).
• Antiplatelet stewardship: evaluate dual-antiplatelet regimens carefully. If bleeding risk outweighs cardiovascular benefit, discuss stopping or spacing doses. Gastroprotection (e.g., a proton-pump inhibitor) may help reduce lower tract irritation.
• NSAID safety: use the lowest effective dose for the shortest possible time. Encourage adequate hydration and avoid combining multiple NSAIDs. In patients with recurrent haematuria, switch to alternative analgesics such as paracetamol.
• Cyclophosphamide precautions: co-prescribe mesna to bind toxic metabolites and enforce vigorous fluid intake to dilute urine. Regular urinalysis can spot early signs of bladder irritation.

Close collaboration between urologist, GP and prescribing specialist is key. By reviewing the indication, adjusting the regimen and using prophylactic measures, many drug-induced cases of haematuria can be prevented or promptly resolved—safeguarding both medication efficacy and patient safety.

9. Exercise-Induced Haematuria

Exercise-induced haematuria describes a transient presence of blood in the urine following vigorous physical activity. It’s most commonly reported by long-distance runners, but can occur in athletes of any discipline—particularly contact sports such as football or rugby. Although usually benign and self-limiting, it’s important to recognise this pattern so that more serious causes of haematuria aren’t overlooked.

The precise mechanisms remain under investigation, but three factors are thought to contribute:

• Bladder wall trauma: repetitive impact—especially when the bladder isn’t fully emptied—can irritate the urothelium and cause small bleeds.
• Renal ischaemia: intense exercise diverts blood flow away from the kidneys, leading to temporary capillary fragility and leakage.
• Dehydration: reduced fluid intake concentrates urine and may make any bleeding more apparent.

Most cases present without pain or other urinary symptoms, and the visible or microscopic blood typically clears within 48–72 hours. Nonetheless, it’s essential to differentiate exercise-induced haematuria from underlying pathology before attributing findings solely to physical exertion.

9.1 Recognising the Pattern

Key clues that suggest exercise rather than disease are:

• Onset immediately after prolonged or high-impact activity.
• Absence of dysuria, urgency or frequency.
• Normal urinalysis apart from red blood cells (no significant protein or white cells).
• Resolution of haematuria within three days of rest and good hydration.
• No detectable abnormalities on initial ultrasound or dipstick tests.

Keeping a simple exercise–urine diary can help confirm the pattern: note the timing of workouts, fluid intake, and any episodes of discoloured urine. If this correlation is consistent and no other symptoms arise, it may be safe to manage conservatively.

9.2 When to Investigate Further

Even with a clear exercise pattern, further evaluation is warranted if:

• Haematuria persists beyond 7 days of rest and rehydration.
• You develop pain—particularly flank or suprapubic discomfort.
• There are accompanying symptoms such as fever, weight loss or urinary changes.
• Initial imaging (for example, ultrasound) reveals an unexpected lesion.
• You have risk factors for other urinary conditions, such as a family history of stones or cancer.

In these situations, arrange a full urological assessment—including microscopy, culture, and possibly cystoscopy or CT imaging—to rule out infections, stones and tumours. Early specialist input ensures that benign exercise-related bleeds aren’t masking more serious disease.

When to Seek Further Evaluation and Referral

Any episode of visible blood in your urine—even if it clears quickly— deserves prompt medical attention. If you notice a red, pink or brown tinge when you pass urine, contact your GP without delay. Microscopic haematuria (blood detected only on dipstick or under the microscope) also needs assessment if it persists on repeat testing or occurs alongside other symptoms.

Key red flags that should trigger urgent review or referral include:

• Persistent or recurrent haematuria over several weeks
• Accompanying unexplained weight loss or fatigue (potential markers for anaemia or malignancy)
• Severe, colicky flank or suprapubic pain
• Signs of systemic illness such as fever, night sweats or rigors
• New-onset lower urinary tract symptoms in men (hesitancy, weak stream, nocturia)
• A family history of kidney disease or urothelial cancer

NICE NG12 recommends an urgent two-week referral for suspected bladder or kidney cancer in adults with visible haematuria, especially those aged 45 and over. The guideline also advises investigating persistent microscopic haematuria when accompanied by risk factors such as smoking, occupational exposures or a history of stones.

What to expect at your GP appointment:

1. Clinical assessment: A detailed history (including drug use and family background) and physical examination.
2. Initial tests: Urine dipstick or microscopy, mid-stream urine culture, full blood count and renal function.
3. Imaging: An ultrasound scan of the kidneys and bladder or, if indicated, a CT urogram.
4. Specialist input: If initial investigations are inconclusive or a suspicious finding emerges, you may be referred for cystoscopy and further urological assessment.

Even if you prefer private care, beginning with a thorough evaluation ensures that any serious underlying condition is ruled out or managed early. Specialist urological consultation—such as with Ashwin Sridhar Urology—offers discreet, expert investigation and treatment, guiding you swiftly through each diagnostic step and onward to the most appropriate care path.

For full referral criteria, see the NICE NG12 guidelines on suspected cancer in primary care.

Next Steps If You Notice Blood in Your Urine

Any episode of blood in your urine—whether you see it yourself or it turns up on a routine dipstick—deserves prompt attention. Start by scheduling a review with your GP to rule out common causes such as infections or stones. Even if an initial assessment seems reassuring, persistent or recurrent haematuria should not be dismissed, as early detection of less obvious conditions often leads to more effective treatment.

A comprehensive evaluation typically involves taking a thorough history (including any medications, family background and lifestyle factors), a physical examination, urinalysis and, if needed, blood tests or imaging. In some cases you may be referred for a cystoscopy or a CT urogram to visualise the urinary tract more closely. Knowing what to expect helps you stay informed and confident throughout the diagnostic process.

For those seeking private, specialist care in London, Mr Ashwin Sridhar offers discreet, tailored consultations and direct access to advanced investigations. Whether you want a second opinion or require expert management of complex urological issues, you can arrange a private consultation with Ashwin Sridhar Urology by visiting our website or calling our clinic.
Book your appointment today to get the clarity and reassurance you need: Ashwin Sridhar Urology.